Research Summary

My research efforts are focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the GI Oncology site committee and an active member of the Phase I committee at UCSF. Nationally, I am co-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, a member of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS), and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am also study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research is focused on publishing the results of three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004).

Education

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

Honors & Awards

  • 1982
    Phi Beta Kappa
  • 1985-82
    Vine Scholarship, University of Minnesota
  • 1982
    May Sine Peterson Award, University of Minnesota
  • 1982
    Alpha Omega Alpha
  • 1995-92
    Molecular Medicine Fellowship, University of California San Francisco

Selected Publications

  1. Whitman J, Allen IE, Bergsland EK, Suh IA, Hope TA Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.  View on PubMed
  2. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.  View on PubMed
  3. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.  View on PubMed
  4. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.  View on PubMed
  5. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of  View on PubMed
  6. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.  View on PubMed
  7. Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?  View on PubMed
  8. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY Reply to S. Boutayeb et al.  View on PubMed
  9. Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.  View on PubMed
  10. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.  View on PubMed
  11. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.  View on PubMed
  12. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.  View on PubMed
  13. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.  View on PubMed
  14. Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.  View on PubMed
  15. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.  View on PubMed
  16. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.  View on PubMed
  17. Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.  View on PubMed
  18. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK Prognostic impact of a large mesenteric mass >2?cm in ileal neuroendocrine tumors.  View on PubMed
  19. Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.  View on PubMed
  20. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.  View on PubMed

Go to UCSF Profiles, powered by CTSI